What Are the Advantages and Disadvantages of Different Renal Replacement Therapies?
Discussion
Kidneys are amazing in that they filter the blood, eliminate toxins, balance fluids and electrolytes plus have a lot of reserve to do the job they need to do even when injured. Therefore, depending on the problem, chronic renal disease (CRD) often allows time before renal replacement therapy (RRT) is needed. RRT currently is dialysis (peritoneal or hemodialysis) or renal transplant. In general, the patient’s own kidneys do the best job for them but there is always a balance between the problems of CRD and its management, versus the potentially improved renal function with RRT. RRT itself though has a diffe...
Source: PediatricEducation.org - September 13, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
NIDCR's Summer 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page.
NIDCR's Summer 2021 E-Newsletter
In this issue:
NIDCR News
Funding Opportunities & Related Notices
NIH/HHS News
Subscribe to NICDR News
Science Advances
Grantee News
NIDCR News
NIDCR to Release Report on Oral Health in America
As a 20-year follow-up to the seminal Oral Health in America: A Report of the Surgeon General, NIDCR will release Oral Health in America: Advances and Challenges in the fall of 2021. The report will illuminate new directions in the prevention an...
Source: NIDCR Science News - July 1, 2021 Category: Dentistry Source Type: news
AI spots healthy stem cells quickly and accurately
(Tokyo Medical and Dental University) Researchers from Tokyo Medical and Dental University (TMDU) have designed a deep learning-based system that accurately identifies individual skin stem cells grown under artificial conditions and tracks their motion. Using this system to perform quality control of stem cell cultures could improve the speed and efficiency of growing skin grafts for use in regenerative medicine and may also be useful for other types of stem cell cultures. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 23, 2021 Category: International Medicine & Public Health Source Type: news
FDA Approves StrataGraft for Deep Partial-Thickness Thermal Burns
WEDNESDAY, June 16, 2021 -- The StrataGraft skin graft is approved for treatment of deep partial-thickness thermal burns in adults, the U.S. Food and Drug Administration announced Tuesday.
The StrataGraft, produced from keratinocytes and dermal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 16, 2021 Category: Pharmaceuticals Source Type: news
New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duration of re...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A comp...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
IMBRUVICA ® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA® plus venetoclax were alive and progression-free at two years.[1] Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. These data ...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Recommendations on Reconstruction After Skin Cancer Resection New Recommendations on Reconstruction After Skin Cancer Resection
To keep the guideline manageable, recommendations are limited to the practice of reconstruction defined as ' cutaneous closure that requires a flap, graft, or tissue rearrangement. 'Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - May 14, 2021 Category: Dermatology Tags: Dermatology News Source Type: news
Scientists Report Creating the First Embryo With Human and Non-Human Primate Cells
In a ground-breaking experiment, researchers have successfully created the first human-monkey chimera. The work, published in the journal Cell, describes the the first embryo containing both human and monkey cells that was cultured for 20 days. Led by Juan Carlos Izpisua Belmonte, the study represents the culmination of decades of work in understanding early embryo development in non-human species, which Belmonte hopes will now apply to humans. But it is bound to raise serious ethical questions about the implications of combining human cells with those from a different species (even if it is a closely related one), and the...
Source: TIME: Health - April 15, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Source Type: news
Fat grafting shows promise for cancer patients with radiation-induced skin injury
(Wolters Kluwer Health) As cancer survival rates improve, more people are living with the aftereffects of cancer treatment. For some patients, these issues include chronic radiation-induced skin injury - which can lead to potentially severe cosmetic and functional problems. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 30, 2021 Category: International Medicine & Public Health Source Type: news
NPWT for Split-Thickness Skin Grafts on Trunk or Neck Wounds NPWT for Split-Thickness Skin Grafts on Trunk or Neck Wounds
Could negative pressure dressings offer another option for maintaining skin graft fixation on the difficult areas of the trunk or neck?Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 8, 2021 Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news
What Are Potential Complications of Breast Surgery?
Discussion
Common reasons for seeing a breast surgeon would include management of benign or malignant masses with or without breast reconstruction, breast augmentation, and other reasons can be infection or trauma that need surgical treatment.
The breast is formed starting around the 6th week of gestation by breast buds along the mammary line. Breasts then develop from the downgrowth of epithelia into the mesenchymal tissue, which continues to grow. Around 8-9 months a pit forms as entry into the lactiferous ducts. “Nipple inversion is caused either by failure of the lactiferous ducts to develop and grow during matur...
Source: PediatricEducation.org - December 14, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
New Data Demonstrate Long-Term Benefit of IMBRUVICA ® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia
This study highlighted the need for cytogenetic/molecular testing before CIT treatment, consistent with clinical treatment guidelines.[8],[9]Real-World Prognostic Biomarker Testing, Treatment Patterns, And Dosing Among Patients With CLL/SLL From the informCLL™ Prospective Observational Registry (Abstract #547)An oral presentation on Monday, December 7, will feature results from the informCLL™ real-world prospective observational registry assessing treatment patterns in the era of novel agents.4 Key Study Findings:· The most common index treatment was IMBRUVICA®; the majority of patients treated with IMBRUVICA® remai...
Source: Johnson and Johnson - December 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA ® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia
December 5, 2020 (RARITAN, N.J.) – New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and showed that, after achieving undetectable minimal residual disease (uMRD) in both the blood and bone marrow with the IMBRUVICA® combination regimen, the one-year disease-free survival (DFS) of patients randomized to discont...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
NIDCR's Winter 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page.
NIDCR's Winter 2020 E-Newsletter
In this issue:
NIDCR News
Funding Opportunities
NIH/HHS News
Funding Notices
Science Advances
Subscribe to NICDR News
Grantee News
NIDCR News
NIDCR Welcomes New Director Rena D’Souza
Rena N. D’Souza, DDS, MS, PhD, was sworn in as the director of NIDCR by NIH Director Francis S. Collins, MD, PhD, on October 13. Prior to joining NIH, Dr. D’Souza was the assistant vice president for academic affairs and education for health sciences at the Un...
Source: NIDCR Science News - December 4, 2020 Category: Dentistry Source Type: news
